Search Results

You are looking at 131 - 140 of 2,687 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Courtney Smith

01-P All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest

Full access

Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer

Kari E. Hacker, Shitanshu Uppal, and Carolyn Johnston

in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/79469 ; and 4

Full access

Management of Primary Central Nervous System Lymphoma

Francois G. El Kamar and Lauren E. Abrey

primary central nervous system lymphomas at presentation . Neurology 2001 ; 57 : 393 – 396 . 13 Jenkins CN Colquhoun IR . Characterization of primary intracranial lymphoma by computed tomography: an analysis of 36 cases and a review of the

Full access

Carcinosarcomas (Malignant Mixed Müllerian Tumor) of the Uterus: Advances in Elucidation of Biologic and Clinical Characteristics

Lauren E. Kernochan and Rochelle L. Garcia

Edited by Kerrin G. Robinson

. 10 Sebenik M Yan Z Khalbuss WE Mittal K . Malignant mixed mullerian tumor of the vagina: case report with review of the literature, immunohistochemical study, and evaluation for human papilloma virus . Hum Pathol 2007 ; 38 : 1282 – 1288

Full access

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017

Al B. Benson III, Michael I. D'Angelica, Daniel E. Abbott, Thomas A. Abrams, Steven R. Alberts, Daniel A. Anaya, Chandrakanth Are, Daniel B. Brown, Daniel T. Chang, Anne M. Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andrea Karachristos, R. Kate Kelley, Robin Kim, Manisha Palta, James O. Park, Vaibhav Sahai, Tracey Schefter, Carl Schmidt, Jason K. Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G. Gary Tian, Jean-Nicolas Vauthey, Alan P. Venook, Andrew X. Zhu, Karin G. Hoffmann, and Susan Darlow

issued a certificate of participation. To participate in this journal CE activity: 1) review the educational content; 2) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/80708 ; and 3) view

Full access

Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons

Eric H. Bent, Eric Wehrenberg-Klee, Eugene J. Koay, Lipika Goyal, and Jennifer Y. Wo

progress, however, prognosis remains poor. The combination of systemic therapy and LRT in this patient group represents a promising approach to improve outcomes. In this review, we discuss the preclinical rationale and emerging clinical evidence for

Full access

Surgical Management of De Novo Stage IV Breast Cancer

Jilma Patrick and Seema Ahsan Khan

journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/64366 ; and 4) view

Full access

Four-Year Disease-Free Remission in a Patient With POLE Mutation–Associated Colorectal Cancer Treated Using Anti–PD-1 Therapy

Michael L. Durando, Sanjay V. Menghani, Jessica L. Baumann, Danny G. Robles, Tovah A. Day, Cyrus Vaziri, and Aaron J. Scott

remained disease-free 48 months after the first pembrolizumab infusion and was transitioned to annual surveillance follow-up in the clinic. Figure 4. CEA level over time, indicating important events (ie, treatment day, scan review) along the disease

Full access

Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer

Brandon A. Dyer, Dmitriy Zamarin, Ramez N. Eskandar, and Jyoti M. Mayadev

survival in patients whose disease fails to respond to standard therapy. 11 , 12 This review highlights the role of immunotherapy in the management of CC, including the immunology of human papillomavirus (HPV) infection and rationale for immunomodulatory

Full access

The Integration of Chemotherapy and Surgery for Bladder Cancer

Matthew D. Galsky, Harry W. Herr, and Dean F. Bajorin

Advanced Bladder Cancer Meta-analysis Collaboration . Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis . Lancet 2003 ; 361 : 1927 – 1934 . 21 Bono AV Benvenuti C Reali L . Adjuvant chemotherapy in